中国科技核心期刊
中国科技论文统计源期刊
中文生物医学期刊文献数据库
中国科学引文数据库(CSCD收录)
中国学术期刊综合评价数据库统计源期刊
《中国学术期刊影响因子年报》统计源期刊
Chinese Journal of Blood Purification ›› 2020, Vol. 19 ›› Issue (09): 581-584.doi: 10.3969/j.issn.1671-4091.2020.09.002
Previous Articles Next Articles
Received:
Revised:
Online:
Published:
Contact:
Abstract: 【Abstract】In China, maintenance peritoneal dialysis (PD) is used in about 15% of the maintenance dialysis patients. Renal anemia is successfully treated in only 40% of the PD patients. The target hemoglobin level for PD population recommended by the international guidelines is ≥115g/L and <130g/L, similar to the target level for hemodialysis patients. However, many evidences have showed that the target of upper hemoglobin level should be higher in PD patients than in hemodialysis patients. The management of renal anemia has experienced three stages: blood transfusion, erythropoietin stimulator and iron supplements. Recently, the hypoxia- inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is introduced, providing a new era of treatment on renal anemia. Clinically, different treatment modalities have different indications and side effects, and individualized strategy based on conditions of the patients should be carried out.
Key words: Renal anemia, Peritoneal dialysis, Advances in diagnosis and treatment
CLC Number:
R459.5 
0 / / Recommend
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
URL: https://www.cjbp.org.cn/EN/10.3969/j.issn.1671-4091.2020.09.002
https://www.cjbp.org.cn/EN/Y2020/V19/I09/581